Cargando…

Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment

Intravesical Mycobacterium bovis Bacillus Calmette–Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae...

Descripción completa

Detalles Bibliográficos
Autores principales: Bach-Griera, Marc, Campo-Pérez, Víctor, Barbosa, Sandra, Traserra, Sara, Guallar-Garrido, Sandra, Moya-Andérico, Laura, Herrero-Abadía, Paula, Luquin, Marina, Rabanal, Rosa Maria, Torrents, Eduard, Julián, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349652/
https://www.ncbi.nlm.nih.gov/pubmed/32344808
http://dx.doi.org/10.3390/vaccines8020198
_version_ 1783557104355770368
author Bach-Griera, Marc
Campo-Pérez, Víctor
Barbosa, Sandra
Traserra, Sara
Guallar-Garrido, Sandra
Moya-Andérico, Laura
Herrero-Abadía, Paula
Luquin, Marina
Rabanal, Rosa Maria
Torrents, Eduard
Julián, Esther
author_facet Bach-Griera, Marc
Campo-Pérez, Víctor
Barbosa, Sandra
Traserra, Sara
Guallar-Garrido, Sandra
Moya-Andérico, Laura
Herrero-Abadía, Paula
Luquin, Marina
Rabanal, Rosa Maria
Torrents, Eduard
Julián, Esther
author_sort Bach-Griera, Marc
collection PubMed
description Intravesical Mycobacterium bovis Bacillus Calmette–Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae, a nontuberculous mycobacterium, has shown outstanding anti-tumor and immunomodulatory capabilities. As no infections due to M. brumae in humans, animals, or plants have been described, the safety and/or toxicity of this mycobacterium have not been previously addressed. In the present study, an analysis was made of M. brumae- and BCG-intravenously-infected severe combined immunodeficient (SCID) mice, M. brumae-intravesically-treated BALB/c mice, and intrahemacoelic-infected-Galleria mellonella larvae. Organs from infected mice and the hemolymph from larvae were processed to count bacterial burden. Blood samples from mice were also taken, and a wide range of hematological and biochemical parameters were analyzed. Finally, histopathological alterations in mouse tissues were evaluated. Our results demonstrate the safety and non-toxic profile of M. brumae. Differences were observed in the biochemical, hematological and histopathological analysis between M. brumae and BCG-infected mice, as well as survival curves rates and colony forming units (CFU) counts in both animal models. M. brumae constitutes a safe therapeutic biological agent, overcoming the safety and toxicity disadvantages presented by BCG in both mice and G. mellonella animal models.
format Online
Article
Text
id pubmed-7349652
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73496522020-07-15 Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment Bach-Griera, Marc Campo-Pérez, Víctor Barbosa, Sandra Traserra, Sara Guallar-Garrido, Sandra Moya-Andérico, Laura Herrero-Abadía, Paula Luquin, Marina Rabanal, Rosa Maria Torrents, Eduard Julián, Esther Vaccines (Basel) Article Intravesical Mycobacterium bovis Bacillus Calmette–Guérin (BCG) immunotherapy remains the gold-standard treatment for non-muscle-invasive bladder cancer patients, even though half of the patients develop adverse events to this therapy. On exploring BCG-alternative therapies, Mycolicibacterium brumae, a nontuberculous mycobacterium, has shown outstanding anti-tumor and immunomodulatory capabilities. As no infections due to M. brumae in humans, animals, or plants have been described, the safety and/or toxicity of this mycobacterium have not been previously addressed. In the present study, an analysis was made of M. brumae- and BCG-intravenously-infected severe combined immunodeficient (SCID) mice, M. brumae-intravesically-treated BALB/c mice, and intrahemacoelic-infected-Galleria mellonella larvae. Organs from infected mice and the hemolymph from larvae were processed to count bacterial burden. Blood samples from mice were also taken, and a wide range of hematological and biochemical parameters were analyzed. Finally, histopathological alterations in mouse tissues were evaluated. Our results demonstrate the safety and non-toxic profile of M. brumae. Differences were observed in the biochemical, hematological and histopathological analysis between M. brumae and BCG-infected mice, as well as survival curves rates and colony forming units (CFU) counts in both animal models. M. brumae constitutes a safe therapeutic biological agent, overcoming the safety and toxicity disadvantages presented by BCG in both mice and G. mellonella animal models. MDPI 2020-04-25 /pmc/articles/PMC7349652/ /pubmed/32344808 http://dx.doi.org/10.3390/vaccines8020198 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bach-Griera, Marc
Campo-Pérez, Víctor
Barbosa, Sandra
Traserra, Sara
Guallar-Garrido, Sandra
Moya-Andérico, Laura
Herrero-Abadía, Paula
Luquin, Marina
Rabanal, Rosa Maria
Torrents, Eduard
Julián, Esther
Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment
title Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment
title_full Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment
title_fullStr Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment
title_full_unstemmed Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment
title_short Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment
title_sort mycolicibacterium brumae is a safe and non-toxic immunomodulatory agent for cancer treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349652/
https://www.ncbi.nlm.nih.gov/pubmed/32344808
http://dx.doi.org/10.3390/vaccines8020198
work_keys_str_mv AT bachgrieramarc mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT campoperezvictor mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT barbosasandra mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT traserrasara mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT guallargarridosandra mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT moyaandericolaura mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT herreroabadiapaula mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT luquinmarina mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT rabanalrosamaria mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT torrentseduard mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment
AT julianesther mycolicibacteriumbrumaeisasafeandnontoxicimmunomodulatoryagentforcancertreatment